SARS-CoV-2 Infection
Conditions
Brief summary
SARS-CoV-2, has caused an international outbreak of respiratory illness termed Covid-19. The investigators used peptides derived from SARS-CoV-2 virus, to study viral-specific immune responses. COV-CREM is a French prospective monocentric study that will evaluate viral-specific cell responses in positive patients for SARS-CoV-2 on the basis of (RT-PCR) assay performed in respiratory tract sample tested by our local Center for Disease Control.
Interventions
Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected.
Sponsors
Centre Hospitalier Universitaire de Besancon
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* COVID-19 PCR positive, * Hospitalized patients with illness of any duration, and/or SpO2 ≤ 92% on room air. * Cohorte C : patients with cancer (hematological malignancies and solid tumors).
Exclusion criteria
* Refusal to participate, * Any immunosuppressive therapy (i.e. corticosteroids \>10mg of hydrocortisone or equivalent dose) within 14 days before the planned start of study, * Active or chronic hepatitis B or C and/or HIV positive (HIV 1/2 antibodies patients), or a known history of active Tuberculosis bacillus, * Active autoimmune disease that required a systemic treatment, with the following exceptions: * Patients with a history of autoimmune-related hypothyroidism who are on thyroid replacement hormone are eligible for the study, * Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study, * Prior allogeneic bone marrow transplantation or prior solid organ transplantation, * Patients currently exposed to chemotherapy, anti-tumor immunotherapy as anti-PD-1, anti-PD-L1, or anti-CTLA4 agent or any immune therapy or biotherapy (except for patients in cohort C), * Previous prescribing of biotherapy or treatment for the management of COVID-19 is not an exclusion criterion, * Patient under guardianship, curatorship or under the protection of justice.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Specific immune responses | During COVID-19 infection or one month after COVID-19 infection | Intensity and diversity of immune responses specific for SARS-COV-2 |
Countries
France
Contacts
Primary ContactMarie KROEMER, PharmD PhD
Backup ContactKevin BOUILLER, MD
Outcome results
None listed